TIL therapy uses a patient's own T cells, expanded in vitro, to target cancer cells, offering a personalized treatment approach. Amtagvi (lifileucel) is the first FDA-approved TIL therapy for advanced ...

A team of researchers has found new insight into why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings may help improve future ways to deliver ...

Concurrent chemoradiotherapy plus cytokine-induced killer cells therapy or observation in patients with locoregionally advanced nasopharyngeal carcinoma: A ten-year follow-up of a randomized, phase II ...

The recent U.S. Food and Drug Administration approval of lifileucel, the first commercial tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma, marks a significant breakthrough in cancer ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. It’s not common for cancer surgeons to turn their focus ...

Until recently, solid tumors — which make up 90% of cancer diagnoses — had no cell therapy. However, that changed in 2024, when the FDA approved a treatment from Iovance Biotherapeutics for advanced ...

Scientists from the Moffitt Cancer Center say they now have a better understanding why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings ...

Cellular therapies, including TIL, TCR, and CAR-T, are transforming lung cancer care by utilizing personalized immune cells to target tumors. TIL therapy, now FDA-approved for solid tumors, shows ...

A new form of tumor infiltrating lymphocyte (TIL) therapy, a form of personalized cancer immunotherapy, dramatically improved the treatment's effectiveness in patients with metastatic gastrointestinal ...

TAMPA, Fla. — The recent U.S. Food and Drug Administration approval of lifileucel, the first commercial tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma, marks a significant ...